IP Library Granted Patent US 7,384,933
Granted Patent B2
US 7,384,933 · App. 11/115,480 · Granted Jun 10, 2008

Derivatives of 2-hydroxytetrahydrofuran and their use as medicaments

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,384,933
App. No.
11/115,480
Granted
Jun 10, 2008
Kind
B2
Abstract

A hydroxytetrahydrofuran of formula wherein A is with the substituents as defined in the specification, having a calpain inhibiting activity and/or an activity which traps the reactive oxygen species useful for treating inflammatory and immunological diseases, cardio-vascular and cerebro-vascular diseases, disorders of the central or peripheral nervous system, osteoporosis, muscular dystrophy, proliferative diseases, cataract, rejection reactions following organ transplants and autoimmune and viral diseases.

Claims (71)

1. A compound selected from the group consisting of:

N-[(3S)-2-methoxytetrahydrofuran-3-yl]-4-methyl2-(3-{[(10H-phenothiazin-2-yloxy)acetyl]amino)}propyl)pentanamide;

N-[(3S)-2-hydroxytetrahydrofuran-3-yl]-4-methyl-2-(3-{[(10H-phenothiazin-2-yloxy)acetyl]amino}propyl)pentanamide;

N-(10H-phenoxazin-2-ylcarbonyl)-L-leucyl-N 1 -[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;

N-(10H-phenoxazin-2-ylcarbonyl)-L-leucyl-N 1 -[(3S)-2-hydroxytetrahydrofuran-3-yl ]L-leucinamide;

and a salt thereof.

2. A therapeutic composition comprising an inhibiting effective amount of a compound of the formula

wherein A is

R 1 , R 2 , R 4 , R 5 and R 6 are independently selected from the group consisting of hydrogen, halogen, OH, alkyl, alkoxy, cyano, nitro and NR 7 R 8 ,

R 7 and R 8 are independently selected from the group consisting of hydrogen, alkyl and —COR 9 ,

R 9 is selected from the group consisting of hydrogen, alkyl and alkoxy,

R 3 is selected from the group consisting of hydrogen, alkyl and —COR 10 ,

R 10 is selected from the group consisting of hydrogen, alkyl and alkoxy, and

W is selected from the group consisting of a bond, —CH 2 —CH 2 —,—CH═CH—, —O—

—S— and —NR 11 — in which

R 11 is hydrogen or alkyl;

X is selected from the group consisting of —CO—, —Y—CO—, —O—Y—CO— and —NR 12 —Y—CO—,

Y is alkylene or haloalkylene,

R 12 is selected from the group consisting of hydrogen, alkyl and —COR 13 ,

R 13 is selected from the group consisting of hydrogen, alkyl, haloalkyl and alkoxy,

AA is, each time that it occurs, selected from the group consisting of —NR 17 -(CH 2 ) 3 —CH—R 18 —CO—, a natural amino acid, a natural amino acid whose side chain carries a reactive chemical function, protected in the form of alkyl or aralkyl ester, alkyl, aralkyl carbamate or alkyl or aralkyl carboxamide, in the form of alkyl or aralkyl ether or alkyl or aralkyl thioether or in the form of alkyl or aralkyl ester or an amino acid of the formula —NR 14 —

(CH 2 ) p —CR 15 R 16 —CO— in which p is 0 or 1,

R 14 is hydrogen or alkyl,

R 15 is hydrogen or alkyl,

R 16 is selected from the group consisting of hydrogen, alkyl, haloalkyl, phenyl, cycloalkyl, cycloalkylalkyl and alkenyl,

R 17 is hydrogen or alkyl and R 18 is hydrogen or alkyl;

n is 2or 3; and

R is selected from the group consisting of hydrogen, alkyl and —CO—R 19 in which R 19 is alkyl; and

or a salt thereof and an inert pharmaceutical carrier.

3. A method of treating osteoporosis and muscular dystrophy in warm-blooded animals comprising administering to warm-blooded animals in need thereof a calpain inhibiting effective amount of a compound of the formula

wherein A is

R 1 , R 2 , R 4 , R 5 and R 6 are independently selected from the group consisting of hydrogen, halogen, OH, alkyl, alkoxy, cyano, nitro and NR 7 R 8 ,

R 7 and R 8 are independently selected from the group consisting of hydrogen, alkyl and —COR 9 ,

R 9 is selected from the group consisting of hydrogen, alkyl and alkoxy,

R 3 is selected from the group consisting of hydrogen, alkyl and —COR 10 ,

R 10 is selected from the group consisting of hydrogen, alkyl and alkoxy, and

W is selected from the group consisting of a bond, —CH 2 —CH 2 —, —CH═CH—, —O—, —S— and —NR 11 — in which

R 11 is hydrogen or alkyl;

X is selected from the group consisting of —CO—, —Y—CO—, —O—Y—CO— and —NR 12 —Y—CO—,

Y is alkylene or haloalkylene,

R 12 is selected from the group consisting of hydrogen, alkyl and —COR 13 ,

R 13 is selected from the group consisting of hydrogen, alkyl, haloalkyl and alkoxy,

AA is, each time that it occurs, selected from the group consisting of —NR 17 —(CH 2 ) 3 —CH—R 18 —CO—, a natural amino acid, a natural amino acid whose side chain carries a reactive chemical function, protected in the form of alkyl or aralkyl ester, alkyl, aralkyl carbamate a alkyl or aralkyl carboxamide, in the form of alkyl or aralkyl ether or alkyl or aralkyl thioether or in the form of alkyl or aralkyl ester or an amino acid of the formula —NR 14 —(CH 2 ) p —CR 15 R 16 —CO— in which p is 0 a 1,

R 14 is hydrogen or alkyl,

R 15 is hydrogen or alkyl,

R 16 is selected from the group consisting of hydrogen, alkyl, haloalkyl, phenyl, cycloalkyl, cycloalkylalkyl and alkenyl,

R 17 is hydrogen or alkyl and R 18 is hydrogen or alkyl;

n is 2 or 3; and

R is selected from the group consisting of hydrogen, alkyl and —CO—R 19 in which R 19 is alkyl; and

or a salt thereof.

4. A method of treating a disorder selected from the group consisting of osteoporosis and muscular dystrophy in warm-blooded animals comprising administering to warm-blooded animals in need thereof an effective amount of a compound of the formula

wherein A is

R 1 , R 2 , R 4 , R 5 and R 6 are independently selected from the group consisting of hydrogen, halogen,

OH, alkyl, alkoxy, cyano, nitro and NR 7 R 8 ,

R 7 and R 8 are independently selected from the group consisting of hydrogen, alkyl and —COR 9,

R 9 is selected from the group consisting of hydrogen, alkyl and alkoxy,

R 3 is selected from the group consisting of hydrogen, alkyl and —COR 10 ,

R 10 is selected from the group consisting of hydrogen, alkyl and alkoxy, and

W is selected from the group consisting of a bond, —CH 2 —CH 2 —, —CH═CH—, —O—, —S— and —NR 11 —in which R 11 is hydrogen or alkyl;

X is selected from the group consisting of —CO—, —Y—CO—, —O—Y—CO— and —NR 12 —Y—CO—,

Y is alkylene or haloalkylene,

R 12 is selected from the group consisting of hydrogen, alkyl and —COR 13 ,

R 13 is selected from the group consisting of hydrogen, alkyl, haloalkyl and alkoxy,

AA is, each time that it occurs, selected from the group consisting of —NR 17 —(CH 2 ) 3 —CH—R 18 —CO—, a natural amino acid, a natural amino acid whose side chain carries a reactive chemical function, protected in the form of alkyl or aralkyl ester, alkyl, aralkyl carbamate or alkyl or aralkyl carboxamide, in the form of alkyl or aralkyl ether or alkyl or aralkyl thioether or in the form of alkyl or aralkyl ester or an amino acid of the formula —NR 14 —(CH 2 ) p —CR 15 R 16 —CO— in which p is 0 or 1,

R 14 is hydrogen or alkyl,

R 15 is hydrogen or alkyl,

R 16 is selected from the group consisting of hydrogen, alkyl, haloalkyl, phenyl, cycloalkyl, cycloalkylalkyl and alkenyl,

R 17 is hydrogen or alkyl and R 18 hydrogen or alkyl;

n is 2 or 3; and

R is selected from the group consisting of hydrogen, alkyl and —CO—R 19 in which R 19 is alkyl; and

or a salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Feb 11, 2009
From: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES
To: IPSEN PHARMA S.A.S.
Reel/Frame 022240/0147 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2005
From: AUVIN, SERGE; CHABRIER DE LASSAUNIERE, PIERRE-ETIENNE
To: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.C.)
Reel/Frame 016707/0696 →